Clinical trial NCT01064687 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly2189265, exenatide, placebo, metformin, pioglitazone
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 Diabetes (T2D) not well controlled on 1, 2, or 3 oral antidiabetic medications

               1. Glycosylated hemoglobin (HbA1c) greater than or equal to 7 and less than or equal
                  to 11 if taking 1 oral antidiabetic medication

               2. HbA1c greater than or equal to 7 and less than or equal to 10 if on 2 or 3 oral
                  antidiabetic medications

          -  Able to tolerate minimum dose of 1500 milligrams (mg) metformin a day and 30 mg
             pioglitazone per day.

          -  Willing to inject subcutaneous (SC) medication up to 2 times per day

          -  Stable weight for 3 months prior to screening

          -  Body mass index (BMI) between 23 and 45 kilograms per meter squared (kg/m^2)

          -  Females of child bearing potential must test negative for pregnancy at screening by
             serum pregnancy test and be willing to use a reliable method of birth control during
             the study and for 1 month following the last dose of study drug.

        Exclusion Criteria:

          -  Type 1 Diabetes

          -  HbA1c equal to or less than 6.5 before randomization or at randomization

          -  Chronic insulin use

          -  Taking drugs to promote weight loss by prescription or over the counter

          -  Taking systemic steroids for greater than 14 days except for topical, eye, nasal, or
             inhaled

          -  History of fluid retention or edema

          -  History of Heart Failure New York Heart Classification II, III, or IV or acute
             myocardial infarction or stroke within 2 months of screening

          -  Gastrointestinal (GI; stomach) problems such as diabetic gastroparesis or bariatric
             surgery (stomach stapling) or chronically taking drugs that directly affect GI
             motility

          -  Hepatitis or liver disease or alanine transaminase (ALT) greater than 2.5 times the
             upper limit of normal

          -  Acute or chronic pancreatitis of any form

          -  Renal disease (kidney) with a serum creatinine of greater than or equal to 1.5
             milligrams per deciliter (mg/dL) for males and greater than or equal to 1.4 mg/dL for
             females, or a creatine clearance of less than 60 milliliters per minute (mL/min)

          -  History (includes family) of type 2A or 2B Multiple Endocrine Neoplasia (MEN 2A or 2B)
             or medullary c-cell hyperplasia or thyroid cancer

          -  A serum calcitonin greater than or equal to 20 picograms per milliliter (pg/mL) at
             screening

          -  Significant active autoimmune disease such as Lupus or Rheumatoid Arthritis

          -  History of or active malignancy except skin or in situ cervical or prostate cancer for
             within last 5 years

          -  Sickle cell, hemolytic anemia, or other hematological condition that may interfere
             with HbA1c testing

          -  Organ transplant except cornea

          -  Have enrolled in another clinical trial within the last 30 days

          -  Have previously signed an informed consent or participated in a LY2189265
             (dulaglutide) study

          -  Have taken a glucagon-like peptide 1 (GLP-1) receptor agonist within the 3 months
             prior to screening